Agenus to Participate at B Riley Securities’ 2023 Virtual Oncology Conference
11 January 2023 - 12:30AM
Agenus (NASDAQ: AGEN), an immuno-oncology company with a broad
pipeline targeting cancer and infectious disease, today announced
that Dr. Garo Armen, Chairman and CEO of Agenus, and Dr. Steven
O’Day, Chief Medical Officer, will participate in a virtual
fireside chat at the B Riley Securities’ 2023 Virtual Oncology
Conference on Wednesday, January 18th at 11:30am ET.
Registration for the webcast can be accessed at
https://brileyoncology22.sequireevents.com/. Following the webcast,
an archived version will be available on the Investors section of
the Agenus website at
https://investor.agenusbio.com/events-and-presentations.
About Agenus
Agenus is a clinical-stage immuno-oncology company focused on
the discovery and development of therapies that engage the body's
immune system to fight cancer and infections. The Company's vision
is to expand the patient populations benefiting from cancer
immunotherapy by pursuing combination approaches that leverage a
broad repertoire of antibody therapeutics, adoptive cell therapies
(through its subsidiary MiNK Therapeutics), and adjuvants (through
its subsidiary SaponiQx). The Company is equipped with a suite of
antibody discovery platforms and a state-of-the-art GMP
manufacturing facility with the capacity to support clinical
programs. Agenus is headquartered in Lexington, MA. For more
information, please visit www.agenusbio.com and our Twitter handle
@agenus_bio. Information that may be important to investors will be
routinely posted on our website and Twitter.
ContactAgenus Inc.Zack ArmenHead of Investor
Relations917-362-1370zack.armen@agenusbio.com
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Apr 2024 to May 2024
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From May 2023 to May 2024